Log in

NYSE:CTLTCatalent Stock Price, Forecast & News

$78.52
+0.22 (+0.28 %)
(As of 05/22/2020 04:00 PM ET)
Add
Compare
Today's Range
$77.75
Now: $78.52
$78.81
50-Day Range
$48.02
MA: $62.86
$78.55
52-Week Range
$31.04
Now: $78.52
$79.93
Volume560,013 shs
Average Volume1.30 million shs
Market Capitalization$12.16 billion
P/E Ratio112.17
Dividend YieldN/A
Beta1.64
Catalent, Inc. provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products worldwide. It operates through four segments: Softgel Technologies, Biologics and Specialty Drug Delivery, Oral Drug Delivery, and Clinical Supply Services. The Softgel Technologies segment formulates, develops, and manufactures prescription and consumer soft capsules for use in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, unit-dose cosmetics, and animal health medicinal preparations. The Biologics and Specialty Drug Delivery segment formulates, develops, and manufactures small molecule and biologic drug products in prefilled syringes, vials and cartridges, blow-fill-seal unit doses, and injectable formats; develops biologic cell lines; manufactures biologic drug substances; and offers bioanalytical development and testing services. The Oral Drug Delivery segment formulates, develops, and manufactures oral dosage forms using proprietary and conventional drug delivery technologies, such as Zydis, OptiDose CR, OptiPact, OptiForm API and Solution Suite, Pharmatek SD Spray Drying, OptiMelt hot melt extrusion, Micron particle size reduction, and FlexDose; and provides stick pack formulation and filling, and analytical development and testing services. The Clinical Supply Services segment offers Manufacturing, packaging, labeling, storage, distribution, and inventory management for drugs and biologics clinical trials; FastChain demand-led clinical supply services; clinical e-solutions and informatics; and comparator sourcing services. The company serves pharmaceutical, biotechnology, and consumer health companies; and companies in other healthcare market segments, such as animal health and medical devices, as well as in cosmetics industries. Catalent, Inc. was founded in 2007 and is headquartered in Somerset, New Jersey.
Read More
Catalent logo

Beat the Market (BTM) Rank

Analyst Opinion: 2.4Community Rank: 2.3Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.27 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
CUSIPN/A
Phone732-537-6200

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$2.52 billion
Cash Flow$3.31 per share
Book Value$14.12 per share

Profitability

Net Income$137.40 million

Miscellaneous

Employees12,300
Market Cap$12.16 billion
Next Earnings Date8/25/2020 (Estimated)
OptionableOptionable

Receive CTLT News and Ratings via Email

Sign-up to receive the latest news and ratings for CTLT and its competitors with MarketBeat's FREE daily newsletter.

Catalent (NYSE:CTLT) Frequently Asked Questions

How has Catalent's stock been impacted by COVID-19 (Coronavirus)?

Catalent's stock was trading at $46.05 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, CTLT stock has increased by 70.5% and is now trading at $78.52. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Catalent?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Catalent in the last year. There are currently 1 hold rating and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Catalent.

When is Catalent's next earnings date?

Catalent is scheduled to release its next quarterly earnings announcement on Tuesday, August 25th 2020. View our earnings forecast for Catalent.

How were Catalent's earnings last quarter?

Catalent Inc (NYSE:CTLT) announced its quarterly earnings data on Tuesday, May, 5th. The company reported $0.50 EPS for the quarter, topping analysts' consensus estimates of $0.45 by $0.05. The firm earned $760.60 million during the quarter, compared to analysts' expectations of $696.10 million. Catalent had a net margin of 4.79% and a return on equity of 14.58%. The company's revenue was up 23.2% on a year-over-year basis. During the same quarter last year, the company earned $0.49 earnings per share. View Catalent's earnings history.

What guidance has Catalent issued on next quarter's earnings?

Catalent issued an update on its FY 2020 Pre-Market earnings guidance on Tuesday, May, 5th. The company provided EPS guidance of 1.79-1.93 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $1.78. The company issued revenue guidance of $2.87-2.95 billion, compared to the consensus revenue estimate of $2.83 billion.

What price target have analysts set for CTLT?

7 brokers have issued 1-year price objectives for Catalent's stock. Their forecasts range from $62.00 to $77.00. On average, they anticipate Catalent's share price to reach $70.00 in the next twelve months. This suggests that the stock has a possible downside of 10.9%. View analysts' price targets for Catalent.

Has Catalent been receiving favorable news coverage?

Media coverage about CTLT stock has trended somewhat negative this week, InfoTrie Sentiment reports. The research group identifies positive and negative media coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Catalent earned a news sentiment score of -1.0 on InfoTrie's scale. They also gave media stories about the company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an effect on the company's share price in the next few days. View the latest news aboutCatalent.

Who are some of Catalent's key competitors?

What other stocks do shareholders of Catalent own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Catalent investors own include Abbott Laboratories (ABT), Alibaba Group (BABA), Energy Transfer LP Unit (ET), Pfizer (PFE), AT&T (T), Thermo Fisher Scientific (TMO), CVS Health (CVS), AbbVie (ABBV), Johnson & Johnson (JNJ) and Amgen (AMGN).

Who are Catalent's key executives?

Catalent's management team includes the following people:
  • Mr. John R. Chiminski, Chairman & CEO (Age 55)
  • Mr. Wetteny N. Joseph, Sr. VP & CFO (Age 47)
  • Mr. Steven L. Fasman, Sr. VP, Gen. Counsel & Corp. Sec. (Age 56)
  • Mr. Jonathan Arnold, Pres of Oral Drug Delivery Bus. Unit (Age 53)
  • Mr. Alessandro Maselli, Pres & COO (Age 47)

What is Catalent's stock symbol?

Catalent trades on the New York Stock Exchange (NYSE) under the ticker symbol "CTLT."

Who are Catalent's major shareholders?

Catalent's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Janus Henderson Group PLC (10.18%), BlackRock Inc. (10.43%), JPMorgan Chase & Co. (4.59%), Champlain Investment Partners LLC (3.17%), Franklin Resources Inc. (2.55%) and State Street Corp (2.43%). Company insiders that own Catalent stock include Alessandro Maselli, Aristippos Gennadios, Barry Littlejohns, Donald E Morel, Jr, Gregory T Lucier, John J Greisch, John R Chiminski, Lance Miyamoto, Michael J Grippo, Peter L Buzy, Ricardo Pravda, Steven L Fasman and William Downie. View institutional ownership trends for Catalent.

Which major investors are selling Catalent stock?

CTLT stock was sold by a variety of institutional investors in the last quarter, including Alyeska Investment Group L.P., Janus Henderson Group PLC, Wellington Management Group LLP, Schroder Investment Management Group, Principal Financial Group Inc., Bernzott Capital Advisors, Nuveen Asset Management LLC, and GW&K Investment Management LLC. Company insiders that have sold Catalent company stock in the last year include Alessandro Maselli, Aristippos Gennadios, Barry Littlejohns, John R Chiminski, Michael J Grippo, Ricardo Pravda, and Steven L Fasman. View insider buying and selling activity for Catalent.

Which major investors are buying Catalent stock?

CTLT stock was bought by a variety of institutional investors in the last quarter, including Thrivent Financial for Lutherans, JPMorgan Chase & Co., BlackRock Inc., Viking Global Investors LP, The Manufacturers Life Insurance Company , Invesco Ltd., Clearbridge Investments LLC, and Federated Hermes Inc.. Company insiders that have bought Catalent stock in the last two years include Donald E Morel, Jr, Gregory T Lucier, John J Greisch, and Peter L Buzy. View insider buying and selling activity for Catalent.

How do I buy shares of Catalent?

Shares of CTLT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Catalent's stock price today?

One share of CTLT stock can currently be purchased for approximately $78.52.

How big of a company is Catalent?

Catalent has a market capitalization of $12.16 billion and generates $2.52 billion in revenue each year. The company earns $137.40 million in net income (profit) each year or $1.62 on an earnings per share basis. Catalent employs 12,300 workers across the globe.

What is Catalent's official website?

The official website for Catalent is www.catalent.com.

How can I contact Catalent?

Catalent's mailing address is 14 SCHOOLHOUSE ROAD, SOMERSET NJ, 08873. The company can be reached via phone at 732-537-6200 or via email at [email protected]

This page was last updated on 5/24/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.